Anaesthetic implications of calcium channel blockers.
Clinical uses of calcium channel blockers are expanding. In addition to the established uses in patients with arrhythmias, angina pectoris or hypertension, newer and to some extent investigational uses indicate widespread application. For instance, their use has been reported in hypertrophic cardiomyopathy and cold cardioplegia, as well as in pulmonary hypertension, antiplatelet therapy, asthma, achalasia and oesophageal spasm, increased intraocular pressure and in cerebral vasospasm. Their use in obstetrical practice has been proposed. Thus, the presentation of a patient who is treated with calcium channel blockers and who requires anaesthesia will become more common. Calcium channel blockers may, under certain circumstances, potentiate haemodynamic and MAC depressive effects of inhalation agents. There is also evidence that the effects of neuromuscular blocking agents may be potentiated. The anaesthetist should be aware that the potential for interactions exists with digoxin, propranolol, quinidine, theophylline or dantrolene. Of interest and some significance are the anaesthetic implications of pathophysiological alterations that can be induced by calcium channel blockers, by affecting lower oesophageal tone, intracranial hypertension, bronchomotor tone (asthma), muscular dystrophy, neuromuscular function, hypoxic pulmonary vasoconstriction, malignant hyperthermia, inhibition of platelet aggregation and hyperkalemia. Despite these significant potential anaesthetic implications and because, at this time, in some instances withdrawal has clearly demonstrated increase in the signs of myocardial ischaemia, it would not seem necessary to recommend preoperative discontinuation of calcium channel blocker medication in patients presenting for anaesthesia. It is, however, appropriate that there is a high index of awareness of potential problems, unless there is some modification in inhalation anaesthetic concentrations and neuromuscular blocker dosage. Monitoring of cardiovascular and neuromuscular functions is essential. Calcium channel blockers would appear to be currently the drugs of choice for angina pectoris, arrhythmias or hypertension in patients with associated chronic obstructive pulmonary disease.
Jenkins
L C
LC
Scoates
P J
PJ
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000758:Anesthesia; D000777:Anesthetics / Q000494:pharmacology; D000818:Animals; D001249:Asthma / Q000503:physiopathology; D002118:Calcium / Q000502:physiology; D002121:Calcium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use*; D003620:Dantrolene / Q000494:pharmacology; D004077:Digoxin / Q000378:metabolism; D004347:Drug Interactions; D004947:Esophagus / Q000187:drug effects; D006801:Humans; D006947:Hyperkalemia / Q000139:chemically induced; D007427:Intracranial Pressure / Q000187:drug effects; D008305:Malignant Hyperthermia / Q000188:drug therapy; D009466:Neuromuscular Blocking Agents / Q000494:pharmacology; D011802:Quinidine / Q000378:metabolism; D013806:Theophylline / Q000378:metabolism; D014661:Vasoconstriction / Q000187:drug effects
D000319:Adrenergic beta-Antagonists; D000777:Anesthetics; D002121:Calcium Channel Blockers; D009466:Neuromuscular Blocking Agents; D004077:Digoxin; D013806:Theophylline; D003620:Dantrolene; D011802:Quinidine; D002118:Calcium